- Home
- ISRL vs IXHL Comparison
ISRL vs IXHL Comparison
Compare ISRL & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- IXHL
- Stock Information
- Founded
- ISRL 2021
- IXHL 2001
- Country
- ISRL United States
- IXHL Australia
- Employees
- ISRL N/A
- IXHL N/A
- Industry
- ISRL Blank Checks
- IXHL
- Sector
- ISRL Finance
- IXHL
- Exchange
- ISRL Nasdaq
- IXHL Nasdaq
- Market Cap
- ISRL 80.7M
- IXHL 78.7M
- IPO Year
- ISRL 2023
- IXHL N/A
- Fundamental
- Price
- ISRL $12.55
- IXHL $1.19
- Analyst Decision
- ISRL
- IXHL
- Analyst Count
- ISRL 0
- IXHL 0
- Target Price
- ISRL N/A
- IXHL N/A
- AVG Volume (30 Days)
- ISRL 4.5K
- IXHL 166.5M
- Earning Date
- ISRL 01-01-0001
- IXHL 05-15-2025
- Dividend Yield
- ISRL N/A
- IXHL N/A
- EPS Growth
- ISRL N/A
- IXHL N/A
- EPS
- ISRL 0.20
- IXHL N/A
- Revenue
- ISRL N/A
- IXHL $98,000.00
- Revenue This Year
- ISRL N/A
- IXHL $2,538.49
- Revenue Next Year
- ISRL N/A
- IXHL $249.95
- P/E Ratio
- ISRL $63.10
- IXHL N/A
- Revenue Growth
- ISRL N/A
- IXHL N/A
- 52 Week Low
- ISRL $11.08
- IXHL $0.08
- 52 Week High
- ISRL $14.00
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- ISRL 48.60
- IXHL 67.84
- Support Level
- ISRL $12.41
- IXHL $0.95
- Resistance Level
- ISRL $12.99
- IXHL $1.66
- Average True Range (ATR)
- ISRL 0.18
- IXHL 0.16
- MACD
- ISRL 0.01
- IXHL 0.10
- Stochastic Oscillator
- ISRL 77.61
- IXHL 67.50
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.